FBRX

424B5 - Forte Biosciences, Inc. (0001419041) (Filer)

8-K - Forte Biosciences, Inc. (0001419041) (Filer)

Forte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,709,936 shares of its common stock at a price to the public of $26.27 per share. In addition, Forte has granted the underwriters a 30-day option to purchase up to an additional 856,490 shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the shares of common stock are being offered by Forte. The gross proceeds from the offering are expected to be approximately $150 million before deducting underwriting discounts and commissions and other offe

424B5 - Forte Biosciences, Inc. (0001419041) (Filer)

Forte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Forte expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock. All of the shares of common stock are being offered by Forte. The proposed offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Forte intends to use the net proceeds of the offering for w

4 - Forte Biosciences, Inc. (0001419041) (Issuer)

4 - Forte Biosciences, Inc. (0001419041) (Issuer)

8-K - Forte Biosciences, Inc. (0001419041) (Filer)

10-K - Forte Biosciences, Inc. (0001419041) (Filer)

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its full year 2025 financial results and provided a business update. "The clinical development for FB102 continues to progress well with important readouts in 2026," said Forte Biosciences CEO Paul Wagner, PhD. "The topline results from our phase 2 celiac disease study is expected in 2026. Based on the strength of the positive results from the FB102 phase 1b CeD trial, which we reported in June 2025, we look forward to the phase 2 data further validating FB102 for the treatment of celiac disease. The FB102 phase 1b vi

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's Board of Directors approved the grant of equity awards in the form of options to purchase an aggregate total of 25,000 shares of common stock to new non-executive employees as a material inducement to such individuals accepting

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's Board of Directors approved the grant of equity awards in the form of options to purchase an aggregate total of 100,000 shares of common stock to new non-executive employees as a material inducement to such individuals acceptin

SCHEDULE 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings. Forte's CEO, Paul Wagner, PhD will be presenting at the Guggenheim Emerging Outlook: Biotech Summit at 8:30 am ET on February 11th hosted at the Lotte New York Palace in New York, NY. Additionally, on March 4th at 1:50 pm ET, Dr. Wagner will be presenting at the TD Cowen 46th Annual Healthcare Conference hosted at the Boston Marriot Copley Place in Boston, MA. March 10-12, Dr. Wagner will be attending the Barclays 28th Annual Global Healthcare Conference hos

4 - Forte Biosciences, Inc. (0001419041) (Issuer)

4 - Forte Biosciences, Inc. (0001419041) (Issuer)

SCHEDULE 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

4 - Forte Biosciences, Inc. (0001419041) (Issuer)

4 - Forte Biosciences, Inc. (0001419041) (Issuer)

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's Board of Directors approved the grant of an equity award in the form of options to purchase a total of 75,000 shares of common stock to a new non-executive employee as a material inducement to such individual accepting employ

Evercore ISI initiated coverage of Forte Biosciences with a rating of Outperform and set a new price target of $65.00

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's Board of Directors approved the grant of an equity award in the form of options to purchase a total of 15,000 shares of common stock to a new non-executive employee as a material inducement to such individual accepting employm

SCHEDULE 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

SCHEDULE 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

10-Q - Forte Biosciences, Inc. (0001419041) (Filer)